Emerging drugs for irritable bowel syndrome.
Emerging drugs for irritable bowel syndrome.
复制标题
DOI：
10.1517/14728214.11.2.293
复制
发表时间：
2006-05-01
影响因子：
3.4
通讯作者：
Mayer, Emeran
中科院分区：
文献类型：
--
作者：
Bradesi, Sylvie;Tillisch, Kirsten;Mayer, Emeran
肠易激综合征（IBS）是最常见的慢性胃肠道疾病之一，但其病理生理学尚不完全清楚，药理治疗仍不令人满意。目前的治疗选择包括一系列旨在使排便习惯正常化、减轻疼痛或治疗共病心理症状的药物。然而，就整体症状缓解和患者满意度而言，这种针对个体症状的方法仍然不令人满意。在过去的十年中，IBS病理生理学的进一步表征为几种候选药物的开发提供了新的和令人兴奋的脑-肠轴不同水平的靶点。临床试验设计的进步将有助于评估这些化合物在不同肠易激综合征患者群体中的作用。
Irritable bowel syndrome (IBS) is one of the most common chronic gastrointestinal disorders, yet its pathophysiology is incompletely understood and pharmacological treatments remain unsatisfactory. Current therapeutic choices include a range of drugs aimed at normalising bowel habits, reducing pain or treating comorbid psychological symptoms. However, this individual symptom-targeted approach remains unsatisfactory in terms of global symptom relief and patient satisfaction. In the last decade, further characterisation of IBS pathophysiology has provided new and exciting targets at different levels of the brain-gut axis for the development of several candidate drugs. Advances in clinical trial design will help to evaluate these compounds in different IBS patient populations.